GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,708.60p
   
  • Change Today:
      3.40p
  • 52 Week High: 1,713.00
  • 52 Week Low: 1,316.00
  • Currency: UK Pounds
  • Shares Issued: 4,144.88m
  • Volume: 7,547,306
  • Market Cap: £70,819m
  • RiskGrade: 129

FDA approves GSK anaemia drug

By Abigail Townsend

Date: Thursday 02 Feb 2023

LONDON (ShareCast) - (Sharecast News) - The US regulator has given the green light to a GSK treatment for anaemia in patients with chronic kidney disease, the medicines and vaccines group confirmed on Thursday.
The FTSE 100 firm said the US Food and Drug Administration had approved Jesduvroq, a once-a-day oral treatment, for adults who have been receiving dialysis for at least four months.

GSK called Jesduvroq the "first innovative medicine for anaemia treatment in over 30 years", adding that chronic kidney disease affected currently around 700m patients worldwide. An estimated one in seven will develop anaemia.

Tony Wood, GSK chief scientific officer, said: "Over the last several decades there has been little innovation in anaemia of CKD. We are proud to have developed Jesduvroq as a new oral treatment where there is a patient desire for more options."

A marketing application for Jesduvroq has been lodged with the European Medicines Agency, with a regulatory decision expected in the first half of 2023. It has already been approved for use in Japan.

The FDA based its assessment on results from GSK's Ascend-D trial, which assessed the efficacy and safety of the drug in treating anaemia in CKD patients.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,708.60p
Change Today 3.40p
% Change 0.20 %
52 Week High 1,713.00
52 Week Low 1,316.00
Volume 7,547,306
Shares Issued 4,144.88m
Market Cap £70,819m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average
55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average
Price Trend
50.74% above the market average50.74% above the market average50.74% above the market average50.74% above the market average50.74% above the market average
71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average
Income
31.40% above the market average31.40% above the market average31.40% above the market average31.40% above the market average31.40% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
26.72% below the market average26.72% below the market average26.72% below the market average26.72% below the market average26.72% below the market average
29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average

What The Brokers Say

Strong Buy 7
Buy 6
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 28-Mar-2024

Time Volume / Share Price
17:14 750,000 @ 1,709.81p
17:04 13,917 @ 1,706.01p
17:04 13,076 @ 1,706.01p
17:04 549 @ 1,706.01p
17:03 172,458 @ 1,706.01p

GSK Key Personnel

CEO Emma Walmsley

Top of Page